ARCUTIS BIOTHERAPEUTICS INC. - COMMON STOCK

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Oct 2024 16:00:00 By Nasdaq GlobeNewswire

New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types

25 Sep 2024 01:00:00 By Nasdaq GlobeNewswire

FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

24 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology

19 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Sep 2024 16:00:00 By Nasdaq GlobeNewswire

Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255

05 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

28 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

22 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update

14 Aug 2024 21:00:03 By Nasdaq GlobeNewswire

Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update

14 Aug 2024 16:00:00 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Aug 2024 16:00:00 By Nasdaq GlobeNewswire

Arcutis to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024

01 Aug 2024 16:00:00 By Nasdaq GlobeNewswire

Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.

29 Jul 2024 07:35:00 By Nasdaq GlobeNewswire

Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis

29 Jul 2024 07:30:00 By Nasdaq GlobeNewswire

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

23 Jul 2024 08:00:01 By Nasdaq GlobeNewswire

Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL

22 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age

09 Jul 2024 16:53:01 By Nasdaq GlobeNewswire

Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis

09 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Jul 2024 16:00:00 By Nasdaq GlobeNewswire

Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference

10 Jun 2024 14:30:00 By Nasdaq GlobeNewswire